A recently developed CLL International Prognostic Index using age, clinical stage, TP53 status, IGHV mutation status, and serum β2-microglobulin has been shown to better predict progression in early CLL [2, 11]. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.